ASSESSMENT OF CARDIOVASCULAR AND RENAL OUTCOMES FOLLOWING DAPAGLIFLOZIN THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE. A-JMRHS. 2026;4(2):1398-1403. doi:10.65605/a-jmrhs.2026.v04.i02.pp1398-1403